10-Q · August 4, 2026
Beam's Q2 revenue contracted from approximately $8.5 million to $0.5 million year over year, and its net loss widened to $122.7 million, producing a $1.18 per-share loss. First-half revenue benefited from a $25.0…
BEAM earnings analysis
10-Q · Filed November 3, 2026 · Our reading of the company's report
The latest report
Beam reported third-quarter revenue of $9.698 million, down from $10 million a year earlier, and a diluted EPS loss of $1.28 versus a $1.10 loss in 2025 Q3. Liquidity was comparatively strong at $1.0 billion, and…
Read full summary
Beam reported third-quarter revenue of $9.698 million, down from $10 million a year earlier, and a diluted EPS loss of $1.28 versus a $1.10 loss in 2025 Q3. Liquidity was comparatively strong at $1.0 billion, and management extended its expected funding runway into mid-2029 assuming a $200 million facility draw. However, the company remains loss-making, dependent on additional financing, and exposed to substantial patent-priority and third-party intellectual-property risks.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-1.28
What stood out
-
Revenue declined and loss widened
Third-quarter revenue was $9.698 million, down approximately 3% from $10 million in the prior-year quarter, while diluted EPS was a $1.28 loss versus a $1.10 loss in 2025 Q3.
-
Liquidity remains substantial
The company reported $1.0 billion of cash, cash equivalents and marketable securities as of September 30, 2026, providing substantial liquidity relative to its current operating needs.
-
Runway extended into mid-2029
Management expects its operating plans to be funded into mid-2029, assuming an additional $200 million draw from the Sixth Street facility, an extension from the prior expectation of at least 12 months of funding.
-
No control deficiencies reported
Management reported that disclosure controls were effective at the reasonable assurance level as of September 30, 2026, and that there were no material changes to internal control over financial reporting during the quarter.
What to watch
-
Runway depends on additional borrowing
The company’s runway depends partly on an additional $200 million draw from the Sixth Street facility; without that financing, the stated mid-2029 funding horizon may not be achieved.
-
Patent-priority appeal threatens licensing
The PTAB ruled on March 26, 2026 that the Boston Licensing Parties had priority in U.S. Interference No. 106,115, but the decision is being appealed. An adverse result could impair access to patents that Beam has an option to license.
-
European IP rights remain uncertain
The filing identifies multiple adverse European patent developments, including revocation of EP3,241,902 B1 in April 2021, revocation of EP2,800,811 B1 and EP3,401,400 B1 in November 2024, and revocation of EP3,597,749 B1 in November 2025, with the latter decision under appeal.
-
Multiple CRISPR interference proceedings
The filing states that U.S. Interference No. 106,126 resumed on March 31, 2026 after its priority phase had been suspended, while proceedings in U.S. Interference No. 106,133 remained suspended as of the filing.
Management's outlook
No quantitative revenue or EPS guidance was provided. Management indicated cash support for operating plans into mid-2029, assuming an additional $200 million draw from the Sixth Street facility.
Earlier filings 4
10-Q · May 7, 2026
Beam Therapeutics reported significant growth in Q1 2026, achieving revenues of $31.7 million, a marked increase from $7.5 million in Q1 2025, alongside reduced net losses of $94.3 million compared to $108.3 million a…
10-K · February 24, 2026
Beam describes a platform-led strategy anchored on proprietary base editors plus multiple delivery modalities (ex vivo and in vivo) to pursue durable, one-time precision genetic medicines. The company is prioritizing…
10-Q · May 6, 2025
Beam reported Q1 license and collaboration revenue of $7.47 million (vs $7.41M a year ago) and GAAP net loss of $109.27 million, or $(1.24) per share. The company materially bolstered liquidity in March 2025, raising…
Smart money in BEAM
Totals from the last full session. Insider and politician figures cover 90 days.
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.
See every BEAM trade live.
The free pages stop at the last full session. Trader shows every trade as it prints.
Start tracking No card needed.